Application of long-chain non-coding RNA (Ribonucleic Acid) as novel AS (Activated Sequence) marker
The invention relates to application of a long-chain non-coding RNA (Ribonucleic Acid) as a novel AS (Activated Sequence) marker, belonging to the field of molecular biology of rheumatism, and a primer for detecting the long-chain non-coding RNA AC105046.1 can be applied to an AS auxiliary diagnosis or curative effect prediction reagent. A specific overexpression sequence and a small interference sequence RNA sequence synthesized according to the full-length sequence of the long-chain non-coding RNA can be applied to an AS targeted therapeutic reagent. The expression of the long-chain non-coding RNA in AS is significantly down-regulated, is inversely proportional to clinical inflammation and platelets, and is in direct proportion to prothrombin time. According to the present invention, with the overexpression of the AC105046.1, the expression level of the AC105046.1 in AS-FLS (AS-PBMC and physiological FLS co-culture) cells can be significantly increased, the expression of inflammatory cytokines in the co-culture AS-FLS can be inhibited, and the expression of the procoagulant index can be inhibited;.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 29. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU JIAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-29, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN116814776 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001356054 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001356054 | ||
| 003 | DE-627 | ||
| 005 | 20240322142318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001356054 | ||
| 035 | |a (EPA)CN116814776 | ||
| 035 | |a (EPA)88127626 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU JIAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of long-chain non-coding RNA (Ribonucleic Acid) as novel AS (Activated Sequence) marker |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-29, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 | ||
| 520 | |a The invention relates to application of a long-chain non-coding RNA (Ribonucleic Acid) as a novel AS (Activated Sequence) marker, belonging to the field of molecular biology of rheumatism, and a primer for detecting the long-chain non-coding RNA AC105046.1 can be applied to an AS auxiliary diagnosis or curative effect prediction reagent. A specific overexpression sequence and a small interference sequence RNA sequence synthesized according to the full-length sequence of the long-chain non-coding RNA can be applied to an AS targeted therapeutic reagent. The expression of the long-chain non-coding RNA in AS is significantly down-regulated, is inversely proportional to clinical inflammation and platelets, and is in direct proportion to prothrombin time. According to the present invention, with the overexpression of the AC105046.1, the expression level of the AC105046.1 in AS-FLS (AS-PBMC and physiological FLS co-culture) cells can be significantly increased, the expression of inflammatory cytokines in the co-culture AS-FLS can be inhibited, and the expression of the procoagulant index can be inhibited; | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a FANG YANYAN |4 aut | |
| 700 | 0 | |a LI XU |4 aut | |
| 700 | 0 | |a HUANG DAN |4 aut | |
| 700 | 0 | |a WANG FANFAN |4 aut | |
| 700 | 0 | |a HE MINGYU |4 aut | |
| 700 | 0 | |a HAN QI |4 aut | |
| 700 | 0 | |a QI YAJUN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 29. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:29 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88127626/publication/CN116814776A1?q=CN116814776 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 29 |c 09 | ||